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The Wnt signaling receptor Fzd9 is essential for
Myc-driven tumorigenesis in pancreatic islets
Mariano F Zacarı́as-Fluck1,* , Toni Jauset1,2,*, Sandra Martı́nez-Martı́n1 , Jastrinjan Kaur1 , Sı́lvia Casacuberta-Serra2 ,
Daniel Massó-Vallés1 , Erika Serrano del Pozo1, Génesis Martı́n-Fernández1, Íñigo González-Larreategui1 ,
Sergio López-Estévez2 , Lamorna Brown-Swigart3 , Marie-Eve Beaulieu1 , Jonathan R Whitfield1 , Babita Madan4,
David M Virshup4 , Gerard I Evan5 , Laura Soucek1,2,6,7
The huge cadre of genes regulated by Myc has obstructed the
identification of critical effectors that are essential for Myc-driven
tumorigenesis. Here, we describe how only the lack of the receptor
Fzd9, previously identified as a Myc transcriptional target, impairs
sustained tumor expansion and β-cell dedifferentiation in a mouse
model ofMyc-driven insulinoma, allows pancreatic islets tomaintain
their physiological structure and affects Myc-related global gene
expression. Importantly, Wnt signaling inhibition in Fzd9-competent
mice largely recapitulates the suppressionof proliferation causedby
Fzd9 deficiency upon Myc activation. Together, our results indicate
that the Wnt signaling receptor Fzd9 is essential for Myc-induced
tumorigenesis in pancreatic islets.
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Introduction
Myc is a highly pleiotropic transcription factor that governs cell
expansion by coordinating diverse cellular processes, including
proliferation, dedifferentiation, biosynthetic metabolism, cell growth,
and angiogenesis (Dang, 2012). Using the Myc-switchable pIns-
MycERTAM;RIP7-Bcl-xL β-cell tumor model in an unbiased reversible
kinetic expression analysis, we previously identified genes required
for maintenance of Myc-driven β-cell tumors. We found a relatively
small subset of Myc target genes whose change in expression
(whether induction or repression) was dependent upon sustained
Myc activity, and that such changes were reversed by deactivation
of Myc and consequent tumor regression. One of these candidate
tumor maintenance genes was Fzd9, a member of the “frizzled” gene
family of Wnt receptors (Lawlor et al, 2006). Fzd9 was significantly
induced within 4 h of acute Myc activation in vivo, its expression was
maintained as long as Myc activity was sustained, and rapidly de-
creased following Myc deactivation and tumor regression (Lawlor
et al, 2006). In addition, Fzd9has been identified as a direct Myc target
gene through expression and ChIP analysis (Lawlor et al, 2006; Sabò
et al, 2014).
Fzd9 is up-regulated in several types of human cancers including
human gastric cancer (Kirikoshi et al, 2001), osteosarcoma (Wang
et al, 2017) and astrocytoma (Zhang et al, 2006). Knockdown of Fzd9
has also been shown to inhibit cell proliferation and motility in
hepatocellular carcinoma cell lines (Fujimoto et al, 2009). However,
as Fzd9 has also shown some tumor suppressor activity in acute
myeloid leukemia (Zhang et al, 2016) and non-small cell lung cancer,
its role in tumorigenesis is still controversial (Winn et al, 2005, 2006).
In this study, we explored the role of Fzd9 in mediating and
maintaining Myc oncogenic function in pIns-MycERTAM;RIP7-Bcl-xL
β−cell tumors. We show that Fzd9 does, indeed, play a critical
function in the development of Myc-driven insulinomas. We, thus,
identify a novel link connecting Myc and the Wnt pathway, which
appears to be a required effector of Myc oncogenic activity in β-cell
tumorigenesis. This implies the existence of a positive feedback
loop, where Wnt/β-catenin signaling activates Myc (He et al, 1998),
and Myc in turn activates Wnt/β-catenin signaling through Fzd9.
Results
Fzd9 is required for Myc-induced β-cell neoplasia
To determine whether Fzd9 plays a significant role in Myc-induced tu-
morigenesis in vivo, pIns-MycERTAM;RIP7-Bcl-xL (MycER;BclXL hereinafter)
mice were crossed into a Fzd9-deficient background (Ranheim et al,
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2005). The size, distribution, number and histological disposition of
pancreatic islets in Fzd9KO/KOmiceappeared identical to that in Fzd9WT/WT
mice (Fig S1).When tamoxifenwas systemically administered to Fzd9WT/WT;
MycER;BclXL and Fzd9KO/KO;MycER;BclXL animals for 3-wk to activate
MycER, control Fzd9WT/WT;MycER;BclXL transgenic mice rapidly developed
grossly hyperplastic insulinomas (Fig 1A and C), whereas Fzd9KO/KO;
MycER;BclXL mice exhibited no detectable β-cell tumor hyperplasia
and pancreatic islets preserved their normal size (Fig 1B and C).
To exclude the possibility that Fzd9 deficiency inhibits MycER ex-
pression or stimulates its degradation, we monitored the presence of
MycER immunohistochemically in β-cells, with an anti-ER antibody. As
expected, MycER expression was undetectable in control MycER
transgene-negative islets of Fzd9KO/KO;BclXL mice, but was confirmed
to be consistently expressed in tamoxifen-treated Fzd9WT/WT;MycER;
BclXL islets andwas evenhigher in Fzd9KO/KO;MycER;BclXL islets (Fig 1D).
Hence, MycER is readily detectable in Fzd9-deficient cells, and therefore
lack of Fzd9 impairs Myc-induced pancreatic β-cell expansion by mech-
anisms unrelated to suppression of MycER expression.
MycER is functionally active in the absence of Fzd9
Since Fzd9 deficiency blocks the appearance of Myc-driven hyperplastic
insulinomas, we next investigated the possibility that MycER is simply no
longer functional in tamoxifen-treated Fzd9KO/KO;MycER;BclXL islets. To
do this, we first ascertainedwhether activatedMycER retains its ability to
drive β-cell proliferation in the absence of Fzd9. After 3 d of acute
tamoxifen treatment, BrdUwas systemically administered to Fzd9KO/KO;
BclXL, Fzd9WT/WT;MycER;BclXL and Fzd9KO/KO;MycER;BclXLmice 3hbefore
euthanasia. Then, pancreata were collected and BrdU incorporation into
β-cells analyzed by immunofluorescence (Fig 2A). Multiple BrdU-positive
β-cellsweredetected inboth Fzd9wild-type (Fzd9WT/WT;MycER;BclXL) and
knockout (Fzd9KO/KO;MycER;BclXL) mice (21.6% ± 7.7% and 24.1% ± 16.4%,
respectively), whereas BrdU incorporation was almost absent from
control MycER transgene-negative islets (Fzd9KO/KO;BclXL; 0.4% ± 0.5%)
(Fig 2B). Thus, at least initially, Myc retains its capacity to drive β-cell
proliferation even in the absence of Fzd9.
Next, to ascertain whether Myc retains its capacity to induce
apoptosis in pancreatic β-cells in the absence of Fzd9, MycER was
continuously activated for 3 d in the β-cells of Fzd9WT/WT;MycER and
Fzd9KO/KO;MycER mice, without co-expression of BclXL. As seen for
proliferation, shrinkage of islets resulting from β-cell apoptosis
(previously shown in Pelengaris et al [2002]) was observed in both
Fzd9-proficient and Fzd9-deficient islets (Fig 2C). Hence, Fzd9 is not
required for Myc-induced β-cell apoptosis.
Finally, additional Myc-dependent phenotypes previously de-
scribed (Soucek et al, 2007), such as recruitment of mast cells (Fig
S2A) and induction of angiogenesis (Fig S2B) were also observed
after 3 d of tamoxifen treatment in Fzd9KO/KO;MycER;BclXL.
Together, these observations indicate that, in the absence of
Fzd9, MycER is still functionally active upon tamoxifen treatment.
Fzd9 absence impairs tumor expansion
If Myc retains its ability, at least initially, to drive β-cell proliferation, why
do islets fail to expand in tamoxifen-treated Fzd9KO/KO;MycER;BclXLmice?
To investigate this, we asked whether Myc-induced β-cell proliferation is
maintained long term in the absence of Fzd9. MycER was activated in
β-cells for 3 wk and BrdU was administered systemically 3 h before
euthanasia. Pancreata were harvested and BrdU incorporation detected
by immunofluorescence (Fig 2D). High levels of BrdU-positive β-cells were
detected in Fzd9WT/WT;MycER;BclXL mice (16.49% ± 5.4%), but, strikingly,
low levels of BrdU-positive cells (2.25% ± 1.49%) were observed in the
Fzd9KO/KO;MycER;BclXLβ-cells. These levelswere similar to thoseobserved
inMycER transgene-negative islets (Fzd9KO/KO;BclXL; 0.52% ± 0.37%) (Fig 2E)
and in stark contrast to the higher levels observed after 3 d (Fig 2B).
Immunohistochemical staining for the proliferation marker Ki67
demonstrated that the proliferative arrest observed in Fzd9KO/KO;MycER;
BclXL islets is in fact a progressive phenomenon already evident at 1 wk
of sustained Myc activation and essentially complete by 3 wk (Fig 2F).
These results suggest that even though proliferation is initially
triggered upon Myc activation in Fzd9KO/KO;MycER;BclXL cells, Myc’s
tumorigenic potential is lost over time due to the lack of Fzd9.
Fzd9 is necessary for MycER–dependent dedifferentiation and
transformation of β-cells
In MycER;BclXL mice, partial Myc-induced dedifferentiation of β-cells
hasbeenpreviously notedasoneof thepleiotropic effects of oncogenic
Myc, responsible for tumorigenesis and expansion of the islets of
Langerhans (Pelengaris et al, 2002). To verify if such an effect was Fzd9-
dependent, we looked at the expression of both insulin and glucagon
(markers of β-cells and α-cells, respectively). As expected, we detected
high insulin expression in control MycER transgene-negative islets
(Fzd9KO/KO;BclXL) (Fig 3A). In contrast, insulin levels were somewhat
repressed upon 3-wk tamoxifen treatment of Fzd9WT/WT;MycER;BclXL
mice because of Myc-induced partial dedifferentiation of β-cells (Fig
3B) (Pelengaris et al, 2002). Intriguingly, however, high levels of insulin
expression were maintained in islets from Fzd9KO/KO;MycER;BclXL mice
after tamoxifen treatment (Fig 3C and D), indicating blunting of Myc-
inducedβ-cell dedifferentiation in the absence of Fzd9. Indeed, pockets
of fully differentiated cells can also be appreciated by hematoxylin and
eosin (H&E) staining, already after 2 wk ofMycER activation in Fzd9KO/KO;
MycER;BclXL but not in Fzd9WT/WT;MycER;BclXL (Fig S3).
Glucagon positive α-cells displayed their typical proportion (~10% of
the total islet cellular content) and distribution at the islet periphery in
Fzd9-deficient mice without the MycER transgene (Fzd9KO/KO;BclXL) (Fig
3A). In contrast, in tamoxifen-treated Fzd9WT/WT;MycER;BclXL mice, Myc
caused the appearance of α-cells scattered throughout the whole islet
(Fig 3B). Notably, Myc did not trigger this relocalization in the absence of
Fzd9 (Fzd9KO/KO;MycER;BclXL mice treated with tamoxifen), where the
α-cells displayed a more physiological distribution, although in a higher
proportion than in control islets (Fig 3C and E).
Overall, these results suggest that Fzd9 is required for Myc to
induce profound and long-lasting dedifferentiation in β-cells, as
part of its tumorigenic program.
Gene expression analysis shows down-regulation of genes
involved in β-cell survival and stress response in the absence of
Fzd9
To identify potential transcriptional changes that could explain the
anti-tumorigenic effect observed in the absence of Fzd9, Fzd9WT/WT;
MycER;BclXL and Fzd9KO/KO;MycER;BclXLmice were treated with
tamoxifen for 3 d and the islet RNA was used for microarray
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Figure 1. The absence of Fzd9 impairs the development of Myc-driven pancreatic insulinomas.
(A, B) H&E staining (4×) of pancreas sections from Fzd9-proficient and (B) Fzd9-deficient mice treated with tamoxifen for 3 wk. (C) Quantification of the islet size from
Fzd9KO/KO;BclXL, Fzd9WT/WT;MycER;BclXL and Fzd9KO/KO;MycER;BclXL mice. (D) Presence of MycER detected by immunofluorescence against ER (red) in these 3-wk treated
islets. Yellow dotted lines define the periphery of the pancreatic islets. Representative images for each of the groups are shown (10×). Data information: in (C), data are
represented asmean ± SD. * and ** indicate P-values below 0.05 and 0.01, respectively (Kruskal–Wallis followed by Dunn’s test). (A, D) Scale bars: 200 μm in (A), 100 μm in
(D).
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Figure 2. Sustained proliferation of pancreatic islets upon MycER activation requires Fzd9.
(A, B) Incorporated BrdU (green) detected by immunofluorescence (10×) after 3 d of tamoxifen treatment and (B) its quantification. Percentages of BrdU-positive cells
per islet from at least threemice per group are represented. (C) Representative H&E staining of pancreas sections frommice treated with tamoxifen for 3 d. Yellow dotted
lines define the periphery of the pancreatic islets (4×). (D, E) Incorporated BrdU detected by immunofluorescence (10×) after 3 wk of tamoxifen treatment and (E) its
quantification. Percentages of BrdU-positive cells per islet from at least threemice per group are represented. (F)Quantification of the proliferationmarker Ki67 in islets
frommice treated for 1 and 3 wk. Percentages of Ki67-positive cells per islet from threemice per group are represented. Data information: in (B, E, F), data are represented
as mean ± SD. (B, E, F) Statistical significance of differences was examined using one-way, in (B, E), or two-way (in F) ANOVA followed by Tukey’s test. ** and *** indicate
P-values below 0.01 and 0.001, respectively. (A, C, D) Scale bars: 100 μm in (A, D), 200 μm in (C).
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analysis. This early 3-d time-point was selected to reveal those
differences in gene expression that could be the cause, and not the
consequence, of the subsequent phenotypic changes (such as
decrease proliferation rate or dedifferentiation of β-cells). Statis-
tical analysis of the microarray (P < 0.05 and fold-change ± 1.2)
identified 933 differentially expressed genes out of 27,747 probes
(Fig 4A and Table S1). Among the genes whose expression is most
decreased in Fzd9KO/KO pancreatic islets compared with Fzd9WT/WT
expression (fold-change < −2.5), we found several early response
genes, comprising transcription factors and other cellular mediators
Figure 3. Fzd9 mediates Myc-induced dedifferentiation of insulin-expressing β-cells.
(A, B, C) Insulin (green) and glucagon (red) detected by immunofluorescence (10×) in pancreatic tissue sections of Fzd9KO/KO;BclXL, (B) Fzd9WT/WT;MycER;BclXL, and (C)
Fzd9KO/KO;MycER;BclXL treated with tamoxifen for 3 wk. (A, B, C, D) Quantification of total insulin intensity in the islets from (A, B, C). (E) Quantification of glucagon positive
cells in the periphery of the islets. Percentages of glucagon positive cells are shown. Data information: in (D, E), data are represented as mean ± SD. (D, E) Statistical
significance of differences was examined using Kruskal–Wallis followed by Dunn’s test (D) and one-way ANOVA followed by Tukey’s test (E). * and ** indicate P-values
below 0.05 and 0.01, respectively. Scale bar: 100 μm.
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Figure 4. The absence of Fzd9 alters the expression of Myc-related, differentiation and Wnt signaling Gene Sets upon MycER activation.
(A) Heat map of differentially expressed genes determined by microarray analysis performed on a pool of multiple isolated islets (~20–40) from each of four Fzd9WT/WT;
MycER;BclXLmice and four Fzd9KO/KO;MycER;BclXLmice. (B, C) Gene sets related to pancreatic differentiation and (C) Myc targets. (D) qRT-PCR analysis of genes related to
Gene Sets shown in (B) (GPC1) and in (C) (POLD2, SRSF7, and RPL34). (E) Immunofluorescence stainings (20×) and quantification of MYC targets MCM5 and PCNA. Total MCM5
intensity and PCNA positive nuclei per islet are shown. (F) Gene sets related to Wnt signaling pathway identified in the Gene Set Enrichment Analysis as differentially
expressed when comparing expression profiles. (G) β-catenin detected by immunofluorescence (10×) in pancreatic tissue sections treated with tamoxifen for 3 d and its
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of β-cell survival and stress response. JUNB and ATF3, for instance,
are known to coordinate a β-cell survival pathway during inflam-
mation (Gurzov et al, 2012), whereas NPAS4 is an important early
mediator of β-cell stress response (Sabatini et al, 2013). Moreover,
RGS2 (Dong et al, 2017) and IRS2 (Blandino-Rosano et al, 2016)
regulate β-cell survival and mass.
In addition, GeneSet Enrichment Analysis (GSEA) revealed significantly
reduced mTORC1 signaling in Fzd9KO/KO mice compared with Fzd9WT/WT
controls. Importantly, mTORC1 signaling is necessary for β-cell prolifer-
ation, as Raptor knockdown has a direct impact on β-cell size, mass, and
survival (Blandino-Rosano et al, 2017) (NES: −2.18, q < 0.001; Table S2).
Differentiation and Myc target gene sets are differentially
expressed in the absence of Fzd9
GSEA showed that several gene sets associated to β-cell differentiation
were differentially expressed inMycER expressing Fzd9KO/KO;MycER;BclXL
compared with Fzd9WT/WT (Table S2). For instance, the expression of
genes involved in developmental processes, including transcriptional
regulation of pancreatic β-cell differentiation (https://reactome.org/
content/detail/R-HSA-1266738) is significantly impaired (NES: −2.223; q:
0.0126). The Hedgehog/Gli pathway, whose up-regulation is responsible
for β-cell dedifferentiation (Landsman et al, 2011), is significantly re-
duced (NES: −2.221, q: 0.0125), as is TGFβRsignaling, also involved inβ-cell
dedifferentiation (Blum et al, 2014) (NES: −1.982, q: 0.0322) (Fig 4B). To-
gether, these results show that several transcriptional programs en-
gaged by Myc in β-cells, normally leading to their dedifferentiation, are
significantly impaired in the absence of Fzd9.
Notably, GSEA also showed that several Myc-related gene sets are
significantly down-regulated (Fig 4C and Table S3) alongwithMyc-related
transcriptional programs like cell cycle, metabolism, and apoptosis (Fig
S4A–C). The fact that the absence of only one Myc target gene is able to
affect the expression of a number of Myc-related signatures reveals Fzd9
as a key effector of Myc-driven reprogramming of pancreatic β-cells.
We validated the transcriptional regulation in pancreatic islets
observed in the GSEA by performing qRT-PCR of some of the
identified differentially regulated genes after 3 d of tamoxifen-
induced MycER activation in Fzd9KO/KO and Fzd9WT/WT mice (Fig 4D).
We observed that, consistent with the microarray data, GPC1 (be-
longing to Developmental Biology Gene Set), RPL34, SRSF7 and
POLD2 (MYC Targets Gene Set), were significantly down-regulated.
This confirms—using a distinct quantitative method—the Fzd9-
mediated transcriptional regulation of several MycER targets pre-
viously observed by microarray analysis.
We complemented this validation approach by performing
immunofluorescence stainings for other down-regulated MYC
target genes (namely, MCM5 and proliferating cell nuclear antigen
[PCNA]) on pancreatic islets after 1 wk of MycER activation and
confirmed their reduced expression in the islets of Fzd9 knockout
mice (Fig 4E).
Wnt signaling is engaged by Fzd9 and acts as a downstream
effector of Myc-induced tumorigenesis
Given the role of Fzd9 in Wnt signaling, this pathway seemed a priori a
good candidate that could contribute to the multiple Myc-dependent
phenotypes observed when MycER is activated. In fact, Wnt signaling has
been shown to regulate pancreatic β-cell proliferation (Rulifson et al,
2007). However, as previously noted, therewas nodetectable difference in
the histology of pancreata from Fzd9KO/KO and Fzd9WT/WT mice (Fig S1),
indicating that the absence of this receptor is not rate limiting at least
during normal development of the organ. Nevertheless, in MycER-
activated islets, there are significant differences in Wnt-related gene
sets between Fzd9 knockout versus wild-type cells (Fzd9KO/KO;MycER;BclXL
versus Fzd9WT/WT;MycER;BclXL) (Fig 4F). Moreover, qRT-PCR analysis of
AXIN1 and JUNB, genes belonging to WNT and β-Catenin Gene Sets, re-
spectively, confirmed their down-regulation, although they did not reach
statistical significance (P = 0.11 and0.099, respectively; Fig S4E). In addition,
immunofluorescence staining forβ-Actin, part of LabbeWNT3A Targets up
Gene Set (Fig 4F), showed that in the absence of Fzd9 expression, β-Actin
levels are significantly lower in pancreatic islets (Fig S4D).
Similarly, immunofluorescence against β-catenin revealed sig-
nificantly increased protein levels of this Wnt signaling downstream
effector in Fzd9WT/WT;MycER;BclXL islets compared with their MycER-
deficient counterpart Fzd9WT/WT;BclXL (Fig 4G), whereas β-catenin
staining remained low in Fzd9KO/KO;MycER;BclXL cells. Hence, the
Wnt signaling pathway, clearly engaged when Myc is active, appears
dramatically affected by the absence of Fzd9.
Given these results and thewell-established role of Frizzled receptors in
Wnt signaling,wewonderedwhetherpharmacologicalWnt inhibitionwould
be capable of recapitulating the Fzd9 tumor-resistant phenotype. To verify
this hypothesis, we made use of C59, a potent inhibitor of porcupine
(PORCN) that blocks Wnt palmitoylation, Wnt secretion and biological ac-
tivity (Proffitt et al, 2013). Fzd9WT/WT;MycER;BclXLmice were pretreated with
C59 for2d, followedby1wkofC59/tamoxifenco-treatment. Then,pancreata
from these C59-treated Fzd9WT/WT;MycER;BclXLmice, aswell asmice treated
with tamoxifenalone (Fzd9KO/KO;BclXL, Fzd9WT/WT;MycER;BclXLandFzd9KO/KO;
MycER;BclXL) were collectedand stained to assess Ki67 positivity. Analysis of
individual islets shows that, as described above (Fig 3D), when MycER is
activated, cell proliferation in Fzd9KO/KO;MycER;BclXL islets was significantly
lower when compared with their Fzd9WT/WT;MycER;BclXL counterparts
(18.28%±3.5%versus35.99%±3.9%).Notably,when theFzd9-proficientmice
were treatedwithC59, theproliferation ratewasalsosignificantlydecreased
(26.05%±3.2%) (Fig4H), indicating thatWnt inhibitionbyC59 isable to largely
mimic the phenotype of the Fzd9-deficient mice.
Discussion
A vast amount of data in the literature points at Wnt signaling as one of
the major culprits in solid and liquid tumors (Zhan et al, 2017) and Wnt
quantification in the islets. Total β-catenin intensity per islet area is shown. (H) Percentage of Ki67-positive cells in individual islets from Fzd9WT/WT;MycER;BclXL and
Fzd9KO/KO;MycER;BclXL after 1 wk of tamoxifen treatment. An additional group of the Fzd9WT/WT;MycER;BclXLmice was pretreated for 2 d with the Wnt inhibitor C59 and then
received both C59 + tamoxifen during 1 wk. Data information: in (D, G, H), data are represented as mean ± SD, whereas in (E), as median and interquartile range. (D, E, G)
Statistical significance of differences was examined using t test (D), Mann-Whitney U test (E) and Tukey’s test (G). *, ** and *** indicate P-values below 0.05, 0.01 and
0.0001, respectively. (E, G) Scale bars: 50 μm in (E), 100 μm in (G). FDR, false discovery rate; NES, normalized enrichment score.
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pathway inhibition via the targeting of Frizzled receptors has been
suggested as a potential strategy to decrease growth and tumorigenicity
of human tumors (Gurney et al, 2012). Our data indicate that simply
inhibiting one receptor at a time (namely Fzd9) could be sufficient to
achieve a significant therapeutic impact at least in some tumorigenic
contexts, with the advantage of reducing potential side effects associated
with the simultaneous inhibition of multiple Frizzled family members.
Whereas Myc expression has been traditionally placed downstream of
the Wnt signaling pathway, as previously discussed, others have indi-
cated otherwise (Cowling & Cole, 2007). Here, we demonstrate for the
first time the key role of theWnt receptor Fzd9 andWnt signaling inMyc-
induced insulinomas. In this context, whereas previous results suggest
that targeting Fzd9 may not be the best strategy for cancer therapy
because of its dual pro- and anti-tumorigenic character (Zeng et al,
2018), our data indicate that it might be at least a valuable target when
up-regulated in Myc-driven malignancies. In addition, our results sug-
gest the existence of a novel positive feedback loop between Myc and
Wnt signaling: deregulation of Myc might enhance Wnt signaling by up-
regulation of Fzd9, which would, at the same time, promote Myc
overexpression/deregulation—because Myc is a bona fide downstream
target of Wnt—thus feeding again Wnt signaling through Fzd9. It should
be noted that both our genetic and pharmacological approach to delete
Fzd9 and interfere with Wnt signaling, respectively, are systemic and not
specific for the islets of Langerhans only. Hence, we cannot exclude that
such a positive feedback loop between Myc and Wnt can also have cell
autonomous implications.
The identification of Fzd9 as a key Myc-driven tumorigenic
effector is particularly relevant in view of the fact that, even if
Myc is one of the “most wanted” cancer targets, several direct,
and indirect Myc inhibition strategies have failed because of lack
of efficacy and high toxicity derived from low specificity (Whitfield
et al, 2017). Thus, identification of key tumorigenic effectors and
their selective targeting represents an alternative strategy to
achieve high therapeutic impact in Myc-deregulated malignan-
cies. Here, we have described a good example of this alternative
approach.
Materials and Methods
Generation and maintenance of genetically engineered mice
pIns-MycERTAM;RIP7-Bcl-xL and Fzd9KO/KO mice have been previ-
ously described (Pelengaris et al, 2002; Zhao et al, 2005). All the
animal studies were performed in accordance with the ARRIVE
guidelines and the 3 Rs rule of Replacement, Reduction and
Refinement principles. Animals were maintained and treated in
accordance with protocols approved by the CEEA (Ethical Com-
mittee for the Use of Experimental Animals) at the Vall d’Hebron
Institute of Oncology. Mice (both males and females) between 8
and 12 wk old were used.
Preparation and administration of tamoxifen and C59
Tamoxifen (Sigma-Aldrich) was dissolved in peanut oil (Thermo
Fisher Scientific) at 10 mg/ml. Aliquots of 1 ml were prepared and
frozen at −20°C. This injectable solution was administered to mice
by intraperitoneal injection (6 μl/g) every 24 h. 1 ml-syringes and
27 G needles were used for injection.
The Wnt inhibitor C59 was formulated in PEG400 (Sigma-Aldrich)
at 2 g/l. C59 in PEG400 was aliquoted and stored at 4°C. Right before
each treatment, an equal amount of water (1:1) was added tomake a
final concentration of 1 g/l of C59 in 50% PEG400. Mice were then
treated with a daily dose of 10 mg/kg by oral gavage for seven
consecutive days. A mixture 1:1 dilution of water and PEG400 was
used as vehicle for C59-untreated animals.
Immunostaining of pancreas sections
18 h after the last administration of tamoxifen, mice were eutha-
nized with CO2 and pancreata collected. For BrdU staining, 150 μl of
BrdU (Sigma-Aldrich) at 5 mg/ml were intraperitoneally injected 2 h
before euthanasia.
For histological analysis, mouse pancreata were fixed with
paraformaldehyde through systemic cardiac perfusion, col-
lected in cassettes and further incubated in paraformaldehyde
for 24 h. Tissues were then paraffin-embedded, and 5-μm
sections cut and stained by H&E. Additional sections were used
to perform immunostaining. In short, sections were deparaffi-
nized, rehydrated, and subjected to high-temperature antigen
retrieval in 10 mM citrate buffer (pH 6.0). Primary antibodies
were as follows: anti-BrdU (Clone BU1/75; Bio-Rad), anti-Ki67
(SP6; Abcam), anti-Meca32 (Meca32; BD Biosciences), anti-insulin
(EPR17359; Abcam), anti-glucagon (K79bB10; Abcam), anti-β-catenin
(D10A8; Cell Signaling), anti-MCM5 (ab75975; Abcam), anti-PCNA
(307904; BioLegend), and anti-β-Actin (A-5441; Sigma-Aldrich).
Samples were incubated with primary antibodies overnight in
blocking buffer (2.5% BSA, 0.3% Triton X-100 in PBS), sections
were washed, and species-appropriate secondary applied, ei-
ther Alexa Fluor 488 dye–conjugated antibodies (Thermo Fisher
Scientific) or Vectastain ABC kit and DAB reagents (Vector Lab-
oratories). Fluorescence antibody-labeled slides were mounted
in DAKO fluorescent mounting medium containing 1 μg/ml DAPI
counterstain.
Microarray analysis of pancreatic islets
Genome-wide expression analysis was performed in isolated pan-
creatic islets. Briefly, tamoxifen-treated Fzd9WT/WT;MycER;BclXL and
Fzd9KO/KO;MycER;BclXL (n = 4) mice were euthanized by cervical
dislocation. Pancreata were inflated with Collagenase P (6 ml/mouse
at 0.7 mg/ml) (Roche) in HBSS injected through the bile duct. Tissues
were transferred to vials containing 5 ml of Collagenase P and in-
cubated for 20 min at 37°C with gentle shaking. Digested pancreata
were poured into 50 ml tubes and washed with cold HBSS by filling
the tube, performing a short spin up to 652g and removing the
supernatant. Pellets were resuspended in 5 ml and exocrine tissue
further removed by filtering the suspension through 100 μm re-
strainers. Then, tissue remaining in the filter was placed in a 6 cm
plate in 4 ml of cold HBSS. Pancreatic islets were visualized with the
help of a magnifier by addition of dithizone at 0.02 g/l, hand-picked
and transferred into a clean 1.5 ml tube.
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RNA from islets was isolated, DNAse-treated and quality
assessed through Agilent 2100 Bioanalyzer. RNA was reverse-
transcribed to generate cDNA. Microarray was performed using a
Mouse Gene Array 2.1 ST (Affimetryx). GSEA was performed using
publicly available software provided by the Broad Institute
(version 3.0) with the Hallmarks, Curated, Motif, gene ontology,
Oncogenic Signatures and Immunological Signatures gene sets
from the MsigDB (Subramanian et al, 2005). The number of
permutations was set to 1,000 and the genes were ranked
according to Signal2Noise. Heat map was generated using Heat
mapper (Babicki et al, 2016). Hierarchical clustering was per-
formed applying complete linkage method and based on Eu-
clidean distance.
qRT-PCR validation of microarray
qRT-PCR validation was performed in isolated pancreatic islets. Briefly,
Fzd9WT/WT;MycER;BclXL (n = 3) and Fzd9KO/KO;MycER;BclXL (n = 3) were
treatedwith tamoxifen for 3dandpancreatic isletswere then isolated from
them following the protocol described in the previous section. RNA was
then extracted from the samples using RNeasy kit (QIAGEN) andquantified
using NanoDrop. Equal amounts of RNA were then DNAse-treated (NEB)
and reverse transcribed to generate cDNA using iScript Reverse Tran-
scription Supermix for RT-qPCR (Bio-Rad). SYBR green qRT-qPCR analysis
was then performed on these cDNA samples with PerfeCTa SYBR Green
FastMix, Low Rox (Quantabio) using QuantStudio 6 FLEX system (Applied
Biosystems). The data thus obtained were analyzed following the com-
parative (ΔΔCT) method described in Livak and Schmittgen (2001). B2M
(Beta-2-microglobulin) was used as the housekeeping gene. Based on our
hypothesis and the data from the microarray, statistical analysis was
performed using one-tailed t test. Sequences of primers used are listed in
Table S4.
Image and statistical analysis
Islet size was quantified using ImageJ. Immunofluorescence (BrdU, In-
sulin, Glucagon, β-catenin, MCM5, PCNA, β-Actin) and Immunohisto-
chemistry (Ki67) stainings were quantified using ImageJ and Qupath
(Bankhead et al, 2017), respectively. All data were represented and
analyzed using GraphPad Prism 6. One-way ANOVA and Tukey’s test, or
Kruskal–Wallis followed by Dunn’s test were used to assess statistical
significance when analyzing three groups of parametric or non-
parametric distributions. Analysis of two groups were performed with
t test or Mann–Whitney. For each experiment, at least three animals per
group were used and multiple islets quantified. Results are shown as
mean ± SD or median and interquartile range, accordingly. Statistical
significance was considered when P < 0.05.
Data Availability
Microarray data were deposited under accession number GSE167073.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.201900490.
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